**Value-based care: a good idea, many caveats**

**A good idea**

The advantages of reorienting the health system toward value-based care are known. First, the focus on ‘service production’ decreases, contrary to hospital financing in several countries, where the payment per service prevails. Unnecessary acts are diminished that do not create value because benefits do not justify their costs. Second, as the focus is on health outcomes, prevention and health promotion are favored. Third, as the focus is not on the provision of services by a particular professional or institution, integration of care is promoted. However, there are major risks that must be taken into account, notably the way(s) in which the idea is conceived, implemented and can be used.

**Implementation (1): the questionable payment for value**

The main practical consequence of value-based care has been the worldwide implementation of value-based payment to health care providers, also known as payment for performance (P4P). This payment model directs financial rewards to those who achieve better results in terms of health, quality of care or satisfaction. Yet, recent reviews point to small effects limited to the short term.

To understand the possible causes of the disappointing results, one can invoke the insufficiency of incentives, or the way they are attributed. Also, the adverse effects of P4P are pointed out, including professionals focusing too much on the indicator values while neglecting other activities. Others have however criticized P4P more fundamentally, pointing out the danger of P4P replacing the professionals’ intrinsic motivation by the search for profit. As a consequence, P4P becomes indispensable to motivate health workers because it has undermined the natural reward of providing good care.

**Implementation (2): exorbitant prices based on value**

In many countries of The Organisation for Economic Co-operation and Development (OECD), the price of new medicines has been based on value for many years (i.e. value-based price in action), through the need, for reimbursement and price definition, to demonstrate that medicines are ‘cost-effective’. In fact, like value, cost-effectiveness means that gains related to therapy justify an additional cost, assessed for each new therapy, by measuring the incremental cost per quality-adjusted life years. The notion of value encourages the public financier to negotiate better prices with the pharmaceutical industry in case drugs are not cost-effective. Yet, this model has proven to be insufficient to suppress price inflation, endangering the sustainability of health systems.

The economic inefficiency of this system has been clearly described. The value-based price means that prices are set according to our ability to pay, that is, the greater the expected gain, the higher the price that we are expected to pay—and that we will pay. This notion rests on a fundamental principle of economics—that consumers define their preferences by the price they are willing to pay. To give a simple example, an antibiotic that saves the life of a newborn child who goes on to live for 80 years, yields a gain of 80 years of life; if a year of life is valued at 30 000 euros, it means that the value-based price of the antibiotic is $80 \times 30,000 = 2.4$ million euros. This is the value-based price that the company that markets the antibiotic could claim.

Why is the antibiotic not sold for 2 million euros in practice? In a competitive market, the price based on value is driven down by the mechanism of competition. In the realm of healthcare, especially when it comes to innovation, we are faced with situations of monopoly exercised by large pharmaceutical companies that distribute products to patients in situations of great need. It is this monopoly, in conjunction with the inelastic need for many therapies, that fuels the emergence of prohibitive prices based on value—far higher than what prices would be in a functional market. Alternatives to prohibitive prices based on value have been pointed out, that is, prices based on development and roll-out costs, presented in a transparent way, together with public and collaborative R&D financing models.

**Implementation (3): value as the consumer’s choice**

This notion of value is originally defined by Michael Porter as the ratio of ‘health outcomes per dollar spent’, with a very cautious definition of health outcomes. On the one hand, it rejects the notion of user satisfaction as a central element, due to the risk of excessive focus on aspects such as the friendliness of the professionals. On the other hand, it highlights the patient subjectivity regarding health outcomes, referring to the measurement of quality of life.

However, the very notion of subjective value questions this cautious view. From an economic perspective, the value corresponds to what the customer/user is willing to pay. On the business side, the rhetoric of ‘value creation’ means, in practice, the ability to produce a service that can be sold at a price higher than its cost, generating profit. Ideally, based on an inexpensive product (e.g. a portion of ground beef), we can produce a product presented in a way that generates the appearance of greater value (a gourmet hamburger) and for which the consumer can be expected to pay an elevated price. ‘Value is created’.

Michael Porter’s own text, mentioning that ‘the value must be defined by the consumer, not by the provider’, does not put an end to this commercial reading. If we assume that the consumer/user must be at the center of the concept of value, then it is their preferences and their subsequent valuation that must dictate what is valuable. The providers are now focused on creating value, in the strict sense that Porter initially gives (quality-adjusted life expectancy), or in the original economic sense of producing a service for which the customer can be expected to pay more. This value perspective assumes that the health sector is a market like others, with informed consumers exercising their freedom of choice according to their preferences. Yet, we have long known that the idea of the rational consumer in health is hardly credible; although increasingly informed, the specific lack of competence in the use of information makes users particularly vulnerable to any manner of quackery (consider the current pandemic).

This deviation can be seen as positive if we include among preferences elements such as humanity in care, but also as negative if it opens the door to a purely commercial view of the provision of care. First, this means abdicating of the notion of evidence-based medicine. If the user wants to take antibiotics, have a cesarean

---

**Viewpoints**

European Journal of Public Health, 1–2

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Public Health Association.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
doi:10.1093/eurpub/ckab026
delivery, or undergo a computerized axial tomography (CAT) scan every time she has a migraine, this is what the service should offer him, because this is what she values. Second, this means abdicating of all equity concerns about resource allocation in healthcare, i.e. ‘like treatment of like individuals’. Indeed, the value-based concept implicitly defines needs according to willingness to pay, so that care is diverted towards those who better express this willingness (the better off) and against those who do not (the worse off).

It is therefore urgent to return to the scientifically robust notions of evidence-based medicine, the health of the population and equity in health so that the concept of value is not adulterated for purposes that are ill-suited to maximizing social well-being.

Conflicts of interest: None declared.

References

1 Porter ME. What is value in health care. N Engl J Med 2010;363:2477–81.
2 Boertjens J, van Manen J, Mikkers M, Sauter W. Introduction: healthcare financing – an international comparison of models and outcomes. In: Sauter W, Boertjens, van Manen J, Mikkers M (eds.) The Law and Policy of Healthcare Financing, Cheltenham (UK), Northampton: Edward Elgar Publishing, 2019.
3 Cashin C, Chi Y-L, Smith PC, et al. In: Cashin C, Chi Y-L, Smith P, Borowitz M, Thomson S (eds.) Paying for Performance in Health Care: Implications for Health System Performance and Accountability. Maidenhead, Berkshire: McGraw-Hill Education (UK), 2014.
4 Mendelson A, Kondo K, Damberg C, et al. The effects of pay-for-performance programs on health, health care use, and processes of care: a systematic review. Ann Intern Med 2017;166:341–53.
5 Gillam SJ, Siriwardena AN, Steel N. Pay-for-performance in the United Kingdom: impact of the quality and outcomes framework—a systematic review. Ann Fam Med 2012;10:461–8.
6 Deci EL, Koestner R, Ryan RM. A meta-analytic review of experiments examining the effects of extrinsic rewards on intrinsic motivation. Psychol Bull 1999;125:627.
7 Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ 2018;19:123–52.
8 Heintz E, Gerber-Grote A, Ghabrí S, EUneHTA Joint Action, et al. Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUneHTA partner countries. Pharmacoeconomics 2016;34:59–76.
9 Mazzucato M. High Cost of New Drugs. BMJ, 2016;354:i4136.
10 Mazzucato M, Semeniuik G. Public financing of innovation: new questions. Oxford Rev Econ Policy 2017;33:24–48.